Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions

Cristiana Forni; Stefano Ferrari; Loretta Loro; Teresa Mazzei; Claudio Beghelli; Angela Biolchini; Patrizia Simoni; Morena Tremosini; Sergio Strazzari; Cristina Puggioli; Gaetano Bacci

Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions

Cristiana Forni, Stefano Ferrari, Loretta Loro, Teresa Mazzei, Claudio Beghelli, Angela Biolchini, Patrizia Simoni, Morena Tremosini, Sergio Strazzari, Cristina Puggioli, Gaetano Bacci

Istituti Ortopedici Rizzoli

Research output: Contribution to journal › Article › peer-review

Abstract

The antiemetic efficacy of granisetron, ondansetron and tropisetron was evaluated in patients treated with cisplatin-Adriamycin (CDP/ADM) and ifosfamide (IFO) by continuous infusion (CI). In all, 90 patients with osteosarcoma were randomly assigned to receive granisetron (2 mg/m²), or ondansetron (5.3 mg/m²), or tropisetron (3.3 mg/m²) plus dexamethasone 8 mg/m². Chemotherapy consisted of CDP (120 mg/m², 48-h CI) followed by ADM (75 mg/m², 24-h CI) and then, in the second cycle, delivered 3 weeks later, IFO 15 g/m² (120-h CI). Complete protection (CP) from emesis was obtained on 59% of the 717 days of treatment, without significant differences among the three study drugs. A significantly higher rate of CP was obtained during chemotherapy with IFO than with CDP/ADM (69% vs 44%; P

Original language	English
Pages (from-to)	131-133
Number of pages	3
Journal	Supportive Care in Cancer
Volume	8
Issue number	2
Publication status	Published - Mar 2000

Keywords

Continuous infusion
Emesis
Granisetron
Ondansetron
Tropisetron

ASJC Scopus subject areas

Oncology
Nursing(all)

Cite this

Forni, C., Ferrari, S., Loro, L., Mazzei, T., Beghelli, C., Biolchini, A., Simoni, P., Tremosini, M., Strazzari, S., Puggioli, C., & Bacci, G. (2000). Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Supportive Care in Cancer, 8(2), 131-133.

Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. / Forni, Cristiana; Ferrari, Stefano; Loro, Loretta et al.

In: Supportive Care in Cancer, Vol. 8, No. 2, 03.2000, p. 131-133.

Research output: Contribution to journal › Article › peer-review

Forni, C, Ferrari, S, Loro, L, Mazzei, T, Beghelli, C, Biolchini, A, Simoni, P, Tremosini, M, Strazzari, S, Puggioli, C & Bacci, G 2000, 'Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions', Supportive Care in Cancer, vol. 8, no. 2, pp. 131-133.

@article{8285a1d694b745499326a9a61121994a,

title = "Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions",

abstract = "The antiemetic efficacy of granisetron, ondansetron and tropisetron was evaluated in patients treated with cisplatin-Adriamycin (CDP/ADM) and ifosfamide (IFO) by continuous infusion (CI). In all, 90 patients with osteosarcoma were randomly assigned to receive granisetron (2 mg/m2), or ondansetron (5.3 mg/m2), or tropisetron (3.3 mg/m2) plus dexamethasone 8 mg/m2. Chemotherapy consisted of CDP (120 mg/m2, 48-h CI) followed by ADM (75 mg/m2, 24-h CI) and then, in the second cycle, delivered 3 weeks later, IFO 15 g/m2 (120-h CI). Complete protection (CP) from emesis was obtained on 59% of the 717 days of treatment, without significant differences among the three study drugs. A significantly higher rate of CP was obtained during chemotherapy with IFO than with CDP/ADM (69% vs 44%; P",

keywords = "Continuous infusion, Emesis, Granisetron, Ondansetron, Tropisetron",

author = "Cristiana Forni and Stefano Ferrari and Loretta Loro and Teresa Mazzei and Claudio Beghelli and Angela Biolchini and Patrizia Simoni and Morena Tremosini and Sergio Strazzari and Cristina Puggioli and Gaetano Bacci",

year = "2000",

month = mar,

language = "English",

volume = "8",

pages = "131--133",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions

AU - Forni, Cristiana

AU - Ferrari, Stefano

AU - Loro, Loretta

AU - Mazzei, Teresa

AU - Beghelli, Claudio

AU - Biolchini, Angela

AU - Simoni, Patrizia

AU - Tremosini, Morena

AU - Strazzari, Sergio

AU - Puggioli, Cristina

AU - Bacci, Gaetano

PY - 2000/3

Y1 - 2000/3

N2 - The antiemetic efficacy of granisetron, ondansetron and tropisetron was evaluated in patients treated with cisplatin-Adriamycin (CDP/ADM) and ifosfamide (IFO) by continuous infusion (CI). In all, 90 patients with osteosarcoma were randomly assigned to receive granisetron (2 mg/m2), or ondansetron (5.3 mg/m2), or tropisetron (3.3 mg/m2) plus dexamethasone 8 mg/m2. Chemotherapy consisted of CDP (120 mg/m2, 48-h CI) followed by ADM (75 mg/m2, 24-h CI) and then, in the second cycle, delivered 3 weeks later, IFO 15 g/m2 (120-h CI). Complete protection (CP) from emesis was obtained on 59% of the 717 days of treatment, without significant differences among the three study drugs. A significantly higher rate of CP was obtained during chemotherapy with IFO than with CDP/ADM (69% vs 44%; P

AB - The antiemetic efficacy of granisetron, ondansetron and tropisetron was evaluated in patients treated with cisplatin-Adriamycin (CDP/ADM) and ifosfamide (IFO) by continuous infusion (CI). In all, 90 patients with osteosarcoma were randomly assigned to receive granisetron (2 mg/m2), or ondansetron (5.3 mg/m2), or tropisetron (3.3 mg/m2) plus dexamethasone 8 mg/m2. Chemotherapy consisted of CDP (120 mg/m2, 48-h CI) followed by ADM (75 mg/m2, 24-h CI) and then, in the second cycle, delivered 3 weeks later, IFO 15 g/m2 (120-h CI). Complete protection (CP) from emesis was obtained on 59% of the 717 days of treatment, without significant differences among the three study drugs. A significantly higher rate of CP was obtained during chemotherapy with IFO than with CDP/ADM (69% vs 44%; P

KW - Continuous infusion

KW - Emesis

KW - Granisetron

KW - Ondansetron

KW - Tropisetron

UR - http://www.scopus.com/inward/record.url?scp=0034009425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034009425&partnerID=8YFLogxK

M3 - Article

C2 - 10739360

AN - SCOPUS:0034009425

VL - 8

SP - 131

EP - 133

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -

Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this